Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Achilles raises £100mm in Series B round

Executive Summary

Achilles Therapeutics Ltd. (cancer immunotherapies) raised £100mm ($121mm) in its Series B round. RA Capital led and was joined by founding investor Syncona and first-time buyers Forbion, Invus, Perceptive Advisors, and Redmile Group. Funds will support two human proof-of-concept studies with a personalized T-cell therapy targeting clonal neoantigens for melanoma and non-small cell lung cancer.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies